(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Untamed life Safe-havens All over the Planet Offering Remarkable Creature Experiences - 2The most effective method to Promoter for Cellular breakdown in the lungs Mindfulness in Your People group
- 3Optimal Beauty Parlor Medicines for Upgraded Wellbeing and Appearance
- 4Scientists detect X-ray glow from interstellar comet 3I/ATLAS extending 250,000 miles into space
- 5Grasping the Course of Evacuation and Extradition in U.S. Migration
- Finding the Universe of Workmanship: Individual Encounters in Imagination
- The Delight of Camper Vans: Choosing the One That Meets Your Requirements
- Top 15 Supportable Design Brands Coming out on top
- Machado ‘presented’ her Nobel Peace Prize medal to Trump
- How will the universe end?
- 5 Chiefs That Changed Our Opinion on Film
- Vote in favor of your Number one Sort of Cap
- From candy cane fishing to ornament switcharoo, here are some of the best games you can play with your loved ones this holiday season
- The Extraordinary Excursion of Dental Embed Innovation
